Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations

被引:18
|
作者
Shubrook, Jay H. [1 ]
Neumiller, Joshua J. [2 ]
Wright, Eugene [3 ]
机构
[1] Touro Univ Calif, Coll Osteopath Med, Vallejo, CA USA
[2] Washington State Univ, Coll Pharm & Pharmaceut Sci, Spokane, WA USA
[3] Charlotte Area Hlth Educ Ctr, Performance Improvement, Charlotte, NC USA
关键词
Diabetic kidney disease; type; 2; diabetes; chronic kidney disease; urinary albumin to creatinine ratio; ANGIOTENSIN-ALDOSTERONE SYSTEM; GLOMERULAR-FILTRATION-RATE; SGLT2; INHIBITORS; CARDIOVASCULAR OUTCOMES; RECEPTOR AGONISTS; GLYCEMIC CONTROL; FINERENONE; ALBUMINURIA; NEPHROPATHY; BLOCKADE;
D O I
10.1080/00325481.2021.2009726
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at high risk of CKD progression and cardiovascular (CV) disease. Prevalence of CKD in patients with T2D is currently around 40% and continues to grow. The increasing number of people with CKD and T2D will ultimately have a significant impact upon health resource use and costs of care for people with T2D. Management of CKD in patients with T2D aims to preserve kidney function to reduce the risk of end-stage kidney disease, CV events, and mortality. Evidence-based recommendations for the treatment of patients with CKD and T2D are provided by several international and national organizations and recommend several lifestyle and pharmacological approaches to help prevent or delay the progression of CKD in patients with T2D. Guidelines include regular screening of patients with T2D for CKD using spot urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (at least annually and at least twice a year if UACR >300 mg/g). Additionally, assessment of vascular complications, together with interventions designed to improve glycemic control and lipid levels, maintain healthy body weight, and optimize blood pressure should be performed. Medications shown to slow progression of CKD include renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, and, more recently, selective, non-steroidal mineralocorticoid receptor antagonists. This review highlights the ongoing challenges facing primary care providers in the management of CKD in patients with T2D including the consideration of comorbidities, adoption of new treatment options, and implementation of individualized care. Achieving consensus for optimal treatment of this disease is critical in providing consistent and appropriate care for all patients. Strategies to improve outcomes should also include use of clear referral criteria, use of a multi-disciplinary approach, and patient education.
引用
收藏
页码:376 / 387
页数:12
相关论文
共 50 条
  • [1] Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes
    Skolnik, Neil S.
    Style, Alyssa J.
    DIABETES THERAPY, 2021, 12 (06) : 1613 - 1630
  • [2] Management of type 2 diabetes in chronic kidney disease
    Triozzi, Jefferson L.
    Parker Gregg, L.
    Virani, Salim S.
    Navaneethan, Sankar D.
    BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [3] A narrative review of new treatment options for chronic kidney disease in type 2 diabetes
    Persson, Frederik
    Borg, Rikke
    Rossing, Peter
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
  • [4] SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
    Wheeler, David C.
    James, June
    Patel, Dipesh
    Viljoen, Adie
    Ali, Amar
    Evans, Marc
    Fernando, Kevin
    Hicks, Debbie
    Milne, Nicola
    Newland-Jones, Philip
    Wilding, John
    DIABETES THERAPY, 2020, 11 (12) : 2757 - 2774
  • [5] Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study
    Chu, Lisa
    Fuller, Mark
    Jervis, Kathyrn
    Ciaccia, Antonio
    Abitbol, Alexander
    CLINICAL THERAPEUTICS, 2021, 43 (09) : 1558 - +
  • [6] Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone
    Ortiz, Alberto
    Arroyo, Roberto Alcazar
    Escribano, Pedro Pablo Casado
    Fernandez-Fernandez, Beatriz
    Deben, Francisco Martinez
    Mediavilla, Juan Diego
    Michan-Dona, Alfredo
    Soler, Maria Jose
    Gorriz, Jose Luis
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (06) : 519 - 531
  • [7] Management of type 2 diabetes mellitus in chronic kidney disease
    Maffioli, Pamela
    Derosa, Giuseppe
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (01) : 95 - 97
  • [8] Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
    Kleinaki, Zoi
    Kapnisi, Stella
    Theodorelou-Charitou, Sofia-Andriani
    Nikas, Ilias P.
    Paschou, Stavroula A.
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2020, 19 (04): : 467 - 476
  • [9] Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes
    Lerma, Edgar V.
    Wilson, Daniel J.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (05) : 501 - 513
  • [10] Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes
    Neil S. Skolnik
    Alyssa J. Style
    Diabetes Therapy, 2021, 12 : 1613 - 1630